Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Merck
Medtronic
Express Scripts
Baxter

Last Updated: September 30, 2022

WEGOVY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Wegovy, and what generic alternatives are available?

Wegovy is a drug marketed by Novo and is included in one NDA. There are five patents protecting this drug.

This drug has ninety-eight patent family members in thirty-two countries.

The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.

DrugPatentWatch® Generic Entry Outlook for Wegovy

Wegovy was eligible for patent challenges on December 5, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 5, 2031. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Drug patent expirations by year for WEGOVY
Drug Prices for WEGOVY

See drug prices for WEGOVY

DrugPatentWatch® Estimated Generic Entry Opportunity Date for WEGOVY
Generic Entry Date for WEGOVY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for WEGOVY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Virginia Commonwealth UniversityPhase 2
Novo Nordisk A/SPhase 2
National Institute of Allergy and Infectious Diseases (NIAID)Phase 2

See all WEGOVY clinical trials

Pharmacology for WEGOVY

US Patents and Regulatory Information for WEGOVY

WEGOVY is protected by five US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of WEGOVY is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting WEGOVY

GLP-1 compositions and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR WEIGHT MANAGEMENT

GLP-1 compositions and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR WEIGHT MANAGEMENT

Acylated GLP-1 compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Acylated GLP-1 compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Use of long-acting GLP-1 peptides
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE

FDA Regulatory Exclusivity protecting WEGOVY

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-005 Jun 4, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-004 Jun 4, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-005 Jun 4, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-005 Jun 4, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-001 Jun 4, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for WEGOVY

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novo Nordisk A/S Wegovy semaglutide EMEA/H/C/005422
Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to
Authorised no no no 2022-01-06
Novo Nordisk A/S Ozempic semaglutide EMEA/H/C/004174
Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.
Authorised no no no 2018-02-08
Novo Nordisk A/S Rybelsus semaglutide EMEA/H/C/004953
Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise, , , as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, in combination with other medicinal products for the treatment of diabetes., , , For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.,
Authorised no no no 2020-04-03
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for WEGOVY

When does loss-of-exclusivity occur for WEGOVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 06224536
Estimated Expiration: See Plans and Pricing

Austria

Patent: 6446
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0607762
Estimated Expiration: See Plans and Pricing

Canada

Patent: 01784
Estimated Expiration: See Plans and Pricing

China

Patent: 1133082
Estimated Expiration: See Plans and Pricing

Patent: 4017062
Estimated Expiration: See Plans and Pricing

Patent: 4402989
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 63839
Estimated Expiration: See Plans and Pricing

Patent: 22546
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 63839
Estimated Expiration: See Plans and Pricing

Patent: 22546
Estimated Expiration: See Plans and Pricing

Germany

Patent: 2006015928
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 28194
Estimated Expiration: See Plans and Pricing

Patent: 800019
Estimated Expiration: See Plans and Pricing

Israel

Patent: 4051
Estimated Expiration: See Plans and Pricing

Japan

Patent: 85037
Estimated Expiration: See Plans and Pricing

Patent: 09463
Estimated Expiration: See Plans and Pricing

Patent: 08533105
Estimated Expiration: See Plans and Pricing

Patent: 10116407
Estimated Expiration: See Plans and Pricing

Patent: 13063984
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 07011220
Estimated Expiration: See Plans and Pricing

Netherlands

Patent: 0936
Estimated Expiration: See Plans and Pricing

Norway

Patent: 7946
Estimated Expiration: See Plans and Pricing

Patent: 18023
Estimated Expiration: See Plans and Pricing

Patent: 075342
Estimated Expiration: See Plans and Pricing

Poland

Patent: 63839
Estimated Expiration: See Plans and Pricing

Patent: 22546
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 63839
Estimated Expiration: See Plans and Pricing

Patent: 22546
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 34019
Estimated Expiration: See Plans and Pricing

Patent: 07134156
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 0707261
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1205272
Estimated Expiration: See Plans and Pricing

Patent: 070120089
Estimated Expiration: See Plans and Pricing

Spain

Patent: 50051
Estimated Expiration: See Plans and Pricing

Patent: 57313
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 62392
Estimated Expiration: See Plans and Pricing

Patent: 72629
Estimated Expiration: See Plans and Pricing

Patent: 0700433
Estimated Expiration: See Plans and Pricing

Patent: 0942255
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering WEGOVY around the world.

Country Patent Number Title Estimated Expiration
Australia 2021208601 Glp-1 compositions and uses thereof See Plans and Pricing
Russian Federation 2007134156 АЦИЛИРОВАННЫЕ GLP-1 СОЕДИНЕНИЯ See Plans and Pricing
Serbia 60432 UPOTREBA GLP-1 PEPTIDA SA DUGIM DEJSTVOM (USE OF LONG-ACTING GLP-1 PEPTIDES) See Plans and Pricing
Japan 2019528237 GLP−1組成物及びその使用 See Plans and Pricing
Taiwan I372629 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for WEGOVY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1863839 C01863839/01 Switzerland See Plans and Pricing PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66604 02.07.2018
1863839 C201830026 Spain See Plans and Pricing PRODUCT NAME: OZEMPIC-SEMAGLUTIDA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1251; DATE OF AUTHORISATION: 20180208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1251; DATE OF FIRST AUTHORISATION IN EEA: 20180208
1863839 18C1017 France See Plans and Pricing PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180212
1863839 300936 Netherlands See Plans and Pricing PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839 132018000000262 Italy See Plans and Pricing PRODUCT NAME: SEMAGLUTIDE(OZEMPIC); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1251, 20180212
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Medtronic
McKinsey
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.